Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-n-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory cancer.

Cox CD, Coleman PJ, Breslin MJ, Whitman DB, Garbaccio RM, Fraley ME, Buser CA, Walsh ES, Hamilton K, Schaber MD, Lobell RB, Tao W, Davide JP, Diehl RE, Abrams MT, South VJ, Huber HE, Torrent M, Prueksaritanont T, Li C, Slaughter DE, Mahan E, Fernandez-Metzler C, Yan Y, Kuo LC, Kohl NE, Hartman GD.

J Med Chem. 2008 Jul 24;51(14):4239-52. doi: 10.1021/jm800386y. Epub 2008 Jun 25.

PMID:
18578472
2.
3.

Kinesin spindle protein (KSP) inhibitors in combination with chemotherapeutic agents for cancer therapy.

Song H, Zhou S, Wang R, Li S.

ChemMedChem. 2013 Nov;8(11):1736-49. doi: 10.1002/cmdc.201300228. Epub 2013 Aug 21. Review.

PMID:
23964020
4.

Recent progress in the identification and clinical evaluation of inhibitors of the mitotic kinesin KSP.

Knight SD, Parrish CA.

Curr Top Med Chem. 2008;8(10):888-904. Review.

PMID:
18673173
5.

Kinesin spindle protein inhibitors in cancer: a patent review (2008 - present).

Jiang C, You Q.

Expert Opin Ther Pat. 2013 Dec;23(12):1547-60. doi: 10.1517/13543776.2013.833606. Epub 2013 Aug 26. Review.

PMID:
23978071
6.

KSP inhibitors as antimitotic agents.

PĂ©rez-Melero C.

Curr Top Med Chem. 2014;14(20):2286-311. Review.

PMID:
25434354
7.
8.

Targeting the kinesin spindle protein: basic principles and clinical implications.

Sarli V, Giannis A.

Clin Cancer Res. 2008 Dec 1;14(23):7583-7. doi: 10.1158/1078-0432.CCR-08-0120. Review.

9.

Progress on kinesin spindle protein inhibitors as anti-cancer agents.

Zhang Y, Xu W.

Anticancer Agents Med Chem. 2008 Aug;8(6):698-704. Review.

PMID:
18690830
10.

Mitotic kinesins: prospects for antimitotic drug discovery.

Bergnes G, Brejc K, Belmont L.

Curr Top Med Chem. 2005;5(2):127-45. Review.

PMID:
15853642
11.
12.

Inhibitors of kinesin motor proteins--research and clinical progress.

Duhl DM, Renhowe PA.

Curr Opin Drug Discov Devel. 2005 Jul;8(4):431-6. Review.

PMID:
16022179
13.

Recent advances in the new generation taxane anticancer agents.

Geney R, Chen J, Ojima I.

Med Chem. 2005 Mar;1(2):125-39. Review.

PMID:
16787308
15.

Tubulin-associated drug targets: Aurora kinases, Polo-like kinases, and others.

Warner SL, Gray PJ, Von Hoff DD.

Semin Oncol. 2006 Aug;33(4):436-48. Review.

PMID:
16890798

Supplemental Content

Support Center